|
1
|
Clark G, Walsh G, Deshpande P and Koffman
G: Improved efficacy of basiliximab over antilymphocyte globulin
induction therapy in paediatric renal transplantation. Nephrol Dial
Transplant. 17:1304–1309. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrer F, Machado S, Alves R, Macário F,
Bastos C, Roseiro A and Mota A: Induction with basiliximab in renal
transplantation. Transplant Proc. 42:467–470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jorge S, Guerra J, Silva S, Santana A,
Mil-Homens C and Prata MM: Induction immunosuppressive therapy in
renal transplantation: Does basiliximab make the difference?
Transplant Proc. 40:693–696. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matl I, Bachleda P, Michalsky R, Navratil
P, Lao M, Treska V, Prestele H, Matthisson M and Korn A:
Basiliximab can be administered safely and effectively in a single
dose on day 1 postrenal transplantation in patients receiving
triple therapy with azathioprine. Transplant Proc. 33:3205–3206.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gravel MT, Arenas JD, Chenault R II, Magee
JC, Rudich S, Maraschio M, DebRoy M, Miller W and Punch JD: Kidney
transplantation from organ donors following cardiopulmonary death
using extracorporeal membrane oxygenation support. Ann Transplant.
9:57–58. 2004.PubMed/NCBI
|
|
6
|
Solez K and Racusen LC: The Banff
classification revisited. Kidney Int. 83:201–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ocampo C, Aristizabal A, Nieto J, Abadia
H, Angel W, Guzman C, Mena A, Vanegas J, Velez C, Aguirre C, et al:
Induction therapies in kidney transplantation: The experience of
hospital Pablo Tobon Uribe, Medellin, Colombia 2005–2010.
Transplant Proc. 43:3359–3363. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu X and Yang X: Peritoneal dialysis in
China: Meeting the challenge of chronic kidney failure. Am J Kidney
Dis. 65:147–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wind J, van Mook WN, Willems ME and van
Heurn LW: Higher organ donation consent rates by relatives of
potential uncontrolled donors versus potential controlled donors
after death. Nephrol Dial Transplant. 27:4219–4223. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vandivort CS, Taber D, McGillicuddy JW,
Bratton C, Chavin K and Baliga P: Protocol based induction therapy
improves rejection rates, complications and transplant event costs
in adult kidney transplant recipients. J Surg Res. 186:6552014.
View Article : Google Scholar
|
|
11
|
Naderi GH, Mehraban D, Ganji MR,
Jafarpouriani M and Latif AH: The outcome of induction therapy with
monoclonal antibodies in kidney transplantation among Iranian
patients: A prospective study. Transplant Proc. 41:2768–2771. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gralla J and Wiseman AC: The impact of
IL2ra induction therapy in kidney transplantation using tacrolimus-
and mycophenolate-based immunosuppression. Transplantation.
90:639–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heldal K, Thorarinsdottir S, Hartmann A,
Leivestad T, Reisæter AV, Foss AE and Midtvedt K: Induction with
interleukin-2 antagonist for transplantation of kidneys from older
deceased donors: an observational study. Transplant Res. 2:2–11.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Y, Zhou P, Han M, Xue CB, Hu XP and Li
C: Basiliximab or antithymocyte globulin for induction therapy in
kidney transplantation: A meta-analysis. Transplant Proc.
42:1667–1670. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Webster AC, Playford EG, Higgins G,
Chapman JR and Craig J: Interleukin 2 receptor antagonists for
kidney transplant recipients. Cochrane Database Syst Rev: CD003897.
2004. View Article : Google Scholar
|
|
16
|
Ledinh H, Bonvoisin C, Weekers L, de
Roover A, Honoré P, Squifflet JP, Meurisse M and Detry O: Results
of kidney transplantation from donors after cardiac death.
Transplant Proc. 42:2407–2414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adu D, Cockwell P, Ives NJ, Shaw J and
Wheatley K: Interleukin-2 receptor monoclonal antibodies in renal
transplantation: Meta-analysis of randomized trials. BMJ.
326:7892003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quiroga I, McShane P, Koo DD, Gray D,
Friend PJ, Fuggle S and Darby C: Major effects of delayed graft
function and cold ischaemia time on renal allograft survival.
Nephrol Dial Transplant. 21:1689–1696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Farney AC, Hines MH, al-Geizawi S, Rogers
J and Stratta RJ: Lessons learned from a single center's experience
with 134 donation after cardiac death donor kidney transplants. J
Am Coll Surg. 212:440–451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Snoeijs MGJ, van Ernest Heurn LW, van Mook
WNKA, Christiaans MH and van Hooff JP: Controlled donation after
cardiac death: A European perspective. Transplantation Reviews.
21:219–229. 2007. View Article : Google Scholar
|
|
21
|
Abt PL, Fisher CA and Singhal AK: Donation
after cardiac death in the US: History and use. J Am Coll Surg.
203:208–225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wagner SJ and Brennan DC: Induction
therapy in renal transplant recipients: How convincing is the
current evidence? Drugs. 72:671–683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Favi E, Gargiulo A, Spagnoletti G, Salerno
MP, Silvestrini N, Valente I and Citterio F: Induction with
basiliximab plus thymoglobulin is effective and safe in old-for-old
renal transplantation: Six-month results of a prospective clinical
study. Transplant Proc. 42:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haririan A, Morawski K, Sillix DH, El-Amm
JM, Garnick J, West MS, Granger DK, Migdal SD and Gruber SA:
Induction therapy with basiliximab versus thymoglobulin in
African-American kidney transplant recipients. Transplantation.
79:716–721. 2005. View Article : Google Scholar : PubMed/NCBI
|
